Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2

@article{Furuhashi2007TreatmentOD,
  title={Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2},
  author={Masato Furuhashi and G{\"u}rol Tuncman and Cem Z. G{\"o}rg{\"u}n and Liza Makowski and Genichi Atsumi and Eric Vaillancourt and Keita Kono and Vladimir R. Babaev and Sergio Fazio and Macrae F Linton and Richard B Sulsky and Jeffrey A. Robl and Rex A. Parker and G{\"o}khan S Hotamisligil},
  journal={Nature},
  year={2007},
  volume={447},
  pages={959-965}
}
Adipocyte fatty-acid-binding protein, aP2 (FABP4) is expressed in adipocytes and macrophages, and integrates inflammatory and metabolic responses. Studies in aP2-deficient mice have shown that this lipid chaperone has a significant role in several aspects of metabolic syndrome, including type 2 diabetes and atherosclerosis. Here we demonstrate that an orally active small-molecule inhibitor of aP2 is an effective therapeutic agent against severe atherosclerosis and type 2 diabetes in mouse… CONTINUE READING
Highly Influential
This paper has highly influenced 10 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 233 extracted citations

Identification of intracellular carriers for the endocannabinoid anandamide.

Proceedings of the National Academy of Sciences of the United States of America • 2009
View 14 Excerpts
Highly Influenced

References

Publications referenced by this paper.
Showing 1-10 of 28 references

Functional in vivo interactions between JNK1 and JNK2 isoforms in obesity and insulin resistance.

Proceedings of the National Academy of Sciences of the United States of America • 2006

Similar Papers

Loading similar papers…